329325-40-8

Basic information

• Product Name: 1-(pyridin-4-yl)-1,3-propanediol
• Synonyms: 1-(pyridin-4-yl)-1,3-propanediol;1-(pyridin-4-yl)propane-1,3-diol
• CAS NO: 329325-40-8
• Molecular Formula: C₈H₁₁NO₂
• Molecular Weight: 153.17844
• Mol File: 329325-40-8.mol
• Article Data: 6

Chemical Properties

• Melting Point: 98-100 °C
• Boiling Point: 343.5±27.0 °C(Predicted)
• Appearance: /
• Density: 1.199±0.06 g/cm3(Predicted)
• PKA: 13.04±0.20(Predicted)
• CAS DataBase Reference: 1-(pyridin-4-yl)-1,3-propanediol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(pyridin-4-yl)-1,3-propanediol(329325-40-8)
• EPA Substance Registry System: 1-(pyridin-4-yl)-1,3-propanediol(329325-40-8)

Safety Data

• Hazardous Substances Data: 329325-40-8(Hazardous Substances Data)

Usage

Chemical structure

1-(pyridin-4-yl)-1,3-propanediol is a chemical compound that contains a pyridine ring and a 1,3-propanediol moiety.

Common use

It is commonly used as a reagent in chemical synthesis, particularly in the preparation of pharmaceuticals and agrochemicals.

Potential uses in medicinal chemistry

It has several potential uses in medicinal chemistry, such as serving as a building block for the synthesis of various biologically active compounds.

Utilization in material development

It can be utilized in the development of new materials.

Key intermediate

It is a key intermediate in the production of other organic compounds.

Upstream product

• 591228-11-4 3-hydroxy-3-(pyridin-4-yl)propionic acid ethyl ester 
• 1122-54-9 methyl (4-pyridyl) ketone 
• 829-45-8 methyl 3-(pyridin-4-yl)-3-oxo-propionate 
• 872-85-5 pyridine-4-carbaldehyde 

Relevant articles and documents

PHOSPHORUS-CONTAINING PRODRUGS OF GEMCITABINE

This invention relates to phosphorus-containing prodrugs of gemcitabine and their use in the treatment of cancer and viral infectious diseases. Compared with the parent drug (i.e., Gemcitabine), the prodrugs of present invention show a significant overall

A prodrug approach towards the development of tricyclic-based FBPase inhibitors

For the purpose of reducing the strong CYP3A4 inhibitory potency of diamide prodrug 4, cyclic prodrugs of tricyclic-based FBPase inhibitors were synthesized. Extensive SAR studies led to the discovery of pyridine-containing cyclic prodrug 20, which strong

Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-β-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma

Cytotoxic nucleosides have proven to be ineffective for the treatment of hepatocellular carcinoma (HCC) due, in part, to their inadequate conversion to their active nucleoside triphosphates (NTP) in the liver tumor and high conversion in other tissues. Th